RIGEL PHARMACEUTICALS INC business relationships
Companies named in RIGEL PHARMACEUTICALS INC’s 10-K filed 2026-03-03, and public companies whose annual reports name RIGEL PHARMACEUTICALS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.5 / 10
- AI naming
- 88 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in RIGEL PHARMACEUTICALS INC’s annual report 8
“GAVRETO was co-marketed by Blueprint and Genentech, a member of Roche Group (Roche), to patients in the US since September 2020 pursuant to a collaboration agreement between Blueprint and Roche, which agreement was terminated effective in February 2024.” SEC filing
“Under the collaboration, CONNECT will include the olutasidenib treatment arm within CONNECT's TarGet study, a molecularly guided Phase 2 umbrella clinical trial for HGG.” SEC filing
“Under the Lilly Agreement, we had the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at two different specified times and as a result receive lesser royalties from sales.” SEC filing
“We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory.” SEC filing
“Global Exclusive License Agreement with Lilly” SEC filing
“As of December 31, 2025, 89 % of our accounts receivable are outstanding invoices to our customers related to product sales in the US, and the remaining 11 % are outstanding invoices from our collaboration partners, mainly Grifols.” SEC filing
“We also have a RIPK1 inhibitor program in clinical development that is being led by our partner Lilly.” SEC filing
“GAVRETO was co-marketed by Blueprint and Genentech, a member of Roche Group (Roche), to patients in the US since September 2020 pursuant to a collaboration agreement between Blueprint and Roche, which agreement was terminated effective in February 2024.” SEC filing
Companies whose annual reports name RIGEL PHARMACEUTICALS INC 1
“...Syk kinase activity in inflammatory responses was first evaluated with Tavalisse, which was co-developed by AstraZeneca/Rigel Pharmaceuticals, Inc. In 2013, AstraZeneca announced results from pivotal Phase III clinical trials that Tavalisse statistically significantly improved ACR20 (a 20% improveme...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.